Clinical trials
Locally Advanced Rectal Carcinoma clinical trials
Below are recruiting locally advanced rectal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 73 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05148767RecruitingPhase 4
UGT1A1-guided irinotecan for locally advanced rectal cancer
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
Hangzhou, ZhejiangAges 18–75 - NCT05201430RecruitingPhase 3
FOLFOXIRI vs CapeOX before surgery for locally advanced rectal cancer
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05300269RecruitingPhase 2
Test drug SHR-1701 with chemo and radiation for rectal cancer
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05136326RecruitingPhase 2
Pre-surgery chemo-radiation for rectal cancer without MGMT
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
MilanAges 18 years+ - NCT05772923Recruiting
Testing rectal cancer organ-preservation after radiation
This trial compares two ways to preserve the rectum/avoid major surgery after radiation: a focused contact x-ray treatment versus waiting longer and then removing only a small area if needed. It may help some people keep more normal bowel function while still controlling the cancer.
Nijmegen, GelderlandAges 18 years+ - NCT06229041RecruitingPhase 3
Chemo and radiation with or without immunotherapy for high-risk rectal cancer
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
BeijingAges 18–75 - NCT06254521RecruitingPhase 2
Tislelizumab plus chemo before surgery for MSS rectal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
Nanning, GuangxiAges 18 years+ - NCT07750951RecruitingPhase 2
Combination therapy before surgery for advanced rectal cancer
This trial tests a combination of two immunotherapy drugs and chemotherapy given before surgery for a type of rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to shrink the tumor and improve the chances of successful surgery.
Xi'an, ShaanxiAges 18 years+ - NCT06653452Recruiting
PET/MRI for rectal cancer treatment response
This study uses a special scan called PET/MRI to see how well treatment works for locally advanced rectal cancer before surgery. It may help doctors choose the best treatment plan for you.
Beijing, Beijing MunicipalityAges 18–75 - NCT07669220RecruitingPhase 2
Short radiation, immunotherapy, and chemo for advanced rectal cancer
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
GuangzhouAges 18–75 - NCT05601505RecruitingPhase 2
DNA blood test–guided treatment before rectal cancer surgery
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
Beijing, Beijing MunicipalityAges 18–75 - NCT07528209RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced rectal cancer
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) before surgery helps treat locally advanced rectal cancer better. The goal is to shrink tumors and improve survival while preserving bowel function when possible.
Guangzhou, GuangdongAges 18–75 - NCT07527026RecruitingPhase 2
Camrelizumab and chemotherapy with radiation for advanced rectal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab) with chemotherapy and radiation to shrink advanced rectal cancer before surgery. The goal is to help more patients have successful surgery with complete tumor removal.
Beijing, Beijing MunicipalityAges 18–75 - NCT07511413Recruiting
Monitoring health in head, neck, lung & rectal cancer
This trial is studying how a monitoring method (bioimpedance) works for people with head and neck, lung, or rectal cancer who are about to start standard treatment. It may help doctors track your health better during therapy.
Candiolo, Torino (TO)Ages 18 years+ - NCT07514754Recruiting
Immunonutrition support during cancer treatment
This study tests whether special nutritional support (called immunonutrition) helps patients with head and neck, lung, or rectal cancer who are receiving chemotherapy, radiation, or immunotherapy. The goal is to see if it improves how well treatment works and how you feel during and after cancer care.
Candiolo, Torino (TO)Ages 18 years+ - NCT06765616RecruitingPhase 2
Immunotherapy with chemo and radiation for rectal cancer before surgery
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–85 - NCT07469306RecruitingPhase 2
Comparing two radiation plans with chemo and immunotherapy for rectal cancer
This study compares two ways of giving radiation therapy for advanced rectal cancer, combined with a chemotherapy pill and an immunotherapy drug. One approach uses a shorter course of radiation before surgery, and the other uses a longer course; researchers want to see which is more effective and safer.
Fuzhou, FujianAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT06276686RecruitingEarly Phase 1
Exercise With Chemoradiotherapy for Locally Advanced Rectal Cancer
This study tests whether adding regular exercise during your standard chemoradiotherapy can help the treatment work better for people with locally advanced rectal cancer. It is designed for patients who have already been offered this type of therapy before surgery.
Cottingham, East YorkshireAges 18 years+ - NCT07393048Recruiting
Personalized ctDNA test to predict rectal cancer treatment response
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06762405RecruitingPhase 3
Testing dostarlimab with short radiation for MSI rectal cancer
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
DijonAges 18 years+ - NCT07372300RecruitingPhase 3
Heat therapy plus standard care for advanced rectal cancer
This trial tests whether adding modulated electro-hyperthermia (a gentle heat treatment) to standard therapy (radiation and chemotherapy) before surgery helps control locally advanced rectal cancer. It is for people whose cancer has not spread to other parts of the body.
Chiayi City, Dalin TownshipAges 20 years+ - NCT07359989Recruiting
Leucine plus chemoradiation before surgery for rectal cancer
This trial tests whether adding leucine (a simple amino acid) to standard chemoradiation before surgery can help shrink rectal cancer and improve outcomes. It is for people with locally advanced rectal cancer that hasn't yet spread to other organs.
Hangzhou, ZhejiangAges 18–80 - NCT07281157RecruitingPhase 2
Liposomal irinotecan, capecitabine and enlonstobart with short radiation for rectal cancer
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Locally Advanced Rectal Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for locally advanced rectal carcinoma?
- Yes. Clin2 currently lists 73 recruiting locally advanced rectal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced rectal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced rectal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Rectal Cancer
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Nasopharyngeal Carcinoma
- Locally Advanced Cervical Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Urothelial Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.